BioCentury on BioBusiness, Finance
Table: Earnings on deck
Back to the parent article
Published on Monday, January 30, 2012
At least 21 profitable biotechs and pharmas are slated
to report earnings this week. Seven are anticipated to post 4Q11 EPS growth of
10% or more, including 16% growth by AstraZeneca plc (LSE:AZN;
NYSE:AZN). The pharma has been boosting its EPS through share buybacks and cost
cuts. In contrast, Eli Lilly and Co. (NYSE:LLY) is expected to post a
27% decline in 4Q11 EPS on a 5% drop in revenues to $5.9 billion. Lilly's
schizophrenia drug Zyprexa olanzapine lost patent exclusivity in
82 words displayed of 413 words total.
Get the Full Text...
All contents Copyright © 1993-2012 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Purchase This Article
Learn what you're missing.
Broaden your Knowledge Base
The BioCentury Publications Package provides the essential coverage and analysis required by global biopharma decision makers.
Take advantage of our free trials and discover why BioCentury is the choice of biopharma professionals around the globe.
Free Trials Begin the Week Following Sign-up
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your records.
close [ X ]